Michael A. Rogawski

26.1k total citations · 5 hit papers
256 papers, 19.6k citations indexed

About

Michael A. Rogawski is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Psychiatry and Mental health. According to data from OpenAlex, Michael A. Rogawski has authored 256 papers receiving a total of 19.6k indexed citations (citations by other indexed papers that have themselves been cited), including 191 papers in Cellular and Molecular Neuroscience, 135 papers in Molecular Biology and 95 papers in Psychiatry and Mental health. Recurrent topics in Michael A. Rogawski's work include Neuroscience and Neuropharmacology Research (171 papers), Ion channel regulation and function (93 papers) and Epilepsy research and treatment (90 papers). Michael A. Rogawski is often cited by papers focused on Neuroscience and Neuropharmacology Research (171 papers), Ion channel regulation and function (93 papers) and Epilepsy research and treatment (90 papers). Michael A. Rogawski collaborates with scholars based in United States, United Kingdom and Italy. Michael A. Rogawski's co-authors include Wolfgang Löscher, Sean D. Donevan, Doodipala Samba Reddy, Roger J. Porter, George K. Aghajanian, Maciej Gąsior, Tushar G. Kokate, Jong M. Rho, Adam L. Hartman and Brian S. Meldrum and has published in prestigious journals such as Nature, New England Journal of Medicine and Cell.

In The Last Decade

Michael A. Rogawski

254 papers receiving 19.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

d -Serine is an endogenous ligand for the glycine site of the N -methyl- d -aspartate receptor

2000 961 citations Michael A. Rogawski et al. profile →
The neurobiology of antiepileptic drugs

2004 891 citations Michael A. Rogawski et al. profile →
Glia and epilepsy: excitability and inflammation

2013 623 citations Michael A. Rogawski et al. profile →
Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds.

1990 568 citations Michael A. Rogawski, Roger J. Porter profile →
Mechanisms of action of currently used antiseizure drugs

2020 317 citations Michael A. Rogawski et al. Neuropharmacology profile →

Peers

Countries citing papers authored by Michael A. Rogawski

Since Specialization

Citations

This map shows the geographic impact of Michael A. Rogawski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael A. Rogawski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael A. Rogawski more than expected).

Fields of papers citing papers by Michael A. Rogawski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael A. Rogawski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael A. Rogawski. The network helps show where Michael A. Rogawski may publish in the future.

Co-authorship network of co-authors of Michael A. Rogawski

This figure shows the co-authorship network connecting the top 25 collaborators of Michael A. Rogawski. A scholar is included among the top collaborators of Michael A. Rogawski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael A. Rogawski. Michael A. Rogawski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Interim analysis of the long‐term efficacy and safety of azetukalner in an ongoing open‐label extension study following a phase 2b clinical trial (X‐TOLE) in adults with focal epilepsy 2025 ·Epilepsia Open ·Jacqueline A. French, Roger J. Porter, Emilio Perucca, Martin J. Brodie, Michael A. Rogawski, Cynthia L. Harden, (unknown), (unknown), (unknown), Gregory N. Beatch, (unknown)	2
2	A randomized, open‐label, two‐treatment crossover study to evaluate the effect of food on the pharmacokinetics of diazepam nasal spray in healthy adults 2022 ·Epilepsia ·Michael A. Rogawski, (unknown)	5
3	Strain differences in the extent of brain injury in mice after tetramethylenedisulfotetramine-induced status epilepticus 2021 ·NeuroToxicology ·(unknown), Eduardo González, (unknown), Dorota Żółkowska, Donald A. Bruun, Douglas J. Rowland, Naomi Saito, Danielle Harvey, Abhijit J. Chaudhari, Michael A. Rogawski, Joel R. Garbow, Pamela J. Lein	2
4	Epilepsy Benchmarks Area III: Improved Treatment Options for Controlling Seizures and Epilepsy-Related Conditions Without Side Effects 2020 ·Epiliepsy currents ·Stephen F. Traynelis, Dennis Dlugos, David C. Henshall, Heather C. Mefford, Michael A. Rogawski, Kevin J. Staley, Penny A. Dacks, Vicky Whittemore, Annapurna Poduri	8
5	Pharmacokinetics of Diazepam Buccal Film in Adult Patients with Epilepsy: Comparison with Diazepam Rectal Gel (4437) 2020 ·Neurology ·Michael A. Rogawski, Allen H. Heller, (unknown), (unknown), Pavel Klein, (unknown), (unknown)	1
6	First‐in‐man allopregnanolone use in super‐refractory status epilepticus 2017 ·Annals of Clinical and Translational Neurology ·Henrikas Vaitkevicius, Aatif M. Husain, Eric S. Rosenthal, Jonathan Rosand, (unknown), (unknown), Michael A. Rogawski, Andrew J. Cole	42
7	Role of GluK1 Kainate Receptors in Seizures, Epileptic Discharges, and Epileptogenesis 2014 ·Journal of Neuroscience ·Brita Fritsch, Janine Reis, Maciej Gąsior, Rafał M. Kamiński, Michael A. Rogawski	37
8	Evidence for the involvement of the kainate receptor subunit GluR6 (GRIK2) in mediating behavioral displays related to behavioral symptoms of mania 2008 ·Molecular Psychiatry ·Galit Shaltiel, Sungho Maeng, Oz Malkesman, Brandon L. Pearson, Robert J. Schloesser, Tyson Tragon, Michael A. Rogawski, Maciej Gąsior, David A. Luckenbaugh, Guanghan Chen, Husseini K. Manji	136
9	GluR5 Kainate Receptors, Seizures, and the Amygdala 2003 ·Annals of the New York Academy of Sciences ·Michael A. Rogawski, (unknown), (unknown), Wayne D. Yonekawa, Melissa Banks, (unknown)	52
10	Topiramate enhances GABAergic transmission and blocks GluR5 kainate receptors in basolateral amygdala interneurons 2003 ·Maria F. M. Braga, (unknown), Michael A. Rogawski	1
11	Selective Antagonism of GluR5 Kainate-Receptor-Mediated Synaptic Currents by Topiramate in Rat Basolateral Amygdala Neurons 2003 ·Journal of Neuroscience ·(unknown), Michael A. Rogawski	183
12	Induction of seizures by the potent K+ channel-blocking scorpion venom peptide toxins tityustoxin-Kα and pandinustoxin-Kα 1999 ·Epilepsy Research ·(unknown), Tushar G. Kokate, Shun Yamaguchi, (unknown), Robert S. Rogowski, M. P. Blaustein, Michael A. Rogawski	43
13	N-Methyl-d-aspartate Receptor Channel Block by the Enantiomeric 6,7-Benzomorphans BIII 277 CL and BIII 281 CL 1998 ·Journal of Pharmacology and Experimental Therapeutics ·Matthias Grauert, Jong M. Rho, Swaminathan Subramaniam, Michael A. Rogawski	4
14	GluR5 kainate receptor mediated synaptic transmission in rat basolateral amygdala in vitro 1998 ·Neuropharmacology ·He Li, Michael A. Rogawski	84
15	Non-N-methyl-D-aspartate receptor antagonism by 3-N-substituted 2,3-benzodiazepines: relationship to anticonvulsant activity. 1994 ·Journal of Pharmacology and Experimental Therapeutics ·Sean D. Donevan, Satoshi Yamaguchi, Michael A. Rogawski	84
16	Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines 1993 ·Trends in Pharmacological Sciences ·Michael A. Rogawski	278
17	THEORETICAL AND PRACTICAL CONSIDERATIONS CONCERNING THE USE OF NMDA ANTAGONISTS IN THE TREATMENT OF THE EPILEPSIES 1992 ·Clinical Neuropharmacology ·Roger J. Porter, Michael A. Rogawski	1
18	Glyburide-sensitive K+ channels in cultured rat hippocampal neurons: activation by cromakalim and energy-depleting conditions. 1991 ·Molecular Pharmacology ·(unknown), Michael A. Rogawski	44
19	Oculocutaneous Albinism and Mental Disorder 1978 ·Human Heredity ·Michael A. Rogawski, Steve J. Funderburk, Stephen D. Cederbaum	17
20	Pre and postsynaptic actions of neuroleptic drugs 1975 ·British Journal of Pharmacology ·Leslie L. Iversen, Richard J. Miller, Michael A. Rogawski	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact